Valuation: ABVC BioPharma, Inc.

Market Cap 30.32M 26.65M 24.76M 22.77M 42.7M 2.93B 43.53M 295M 115M 1.43B 114M 111M 4.97B P/E 2024
-1.4x
P/E 2025 -5.42x
Enterprise Value 33.05M 29.05M 26.99M 24.82M 46.54M 3.19B 47.44M 322M 126M 1.56B 124M 121M 5.41B EV / Sales 2024
19.8x
EV / Sales 2025 -
Free-Float
79.2%
Yield 2024 *
-
Yield 2025 -
1 day+1.69%
1 week-6.25%
Current month-24.05%
1 month-9.09%
3 months+1.69%
6 months-42.31%
Current year-43.66%
1 week 1.15
Extreme 1.15
1.28
1 month 1.15
Extreme 1.15
2.15
Current year 0.88
Extreme 0.8801
2.43
1 year 0.88
Extreme 0.8801
3.4
3 years 0.4
Extreme 0.4
6.87
5 years 0.4
Extreme 0.4
116.9
10 years 0.4
Extreme 0.4
378
Manager TitleAgeSince
Chief Executive Officer 40 2023-06-22
Chief Executive Officer 39 2015-06-30
Chief Tech/Sci/R&D Officer 72 2023-06-12
Director TitleAgeSince
Director/Board Member 61 2022-07-09
Director/Board Member 70 -
Chairman 39 2015-06-30
Date Insider Type Main position Quantity % Market Cap.
5/20/22 Other

Chairman

7,908,805 26.0954%
8/2/21 Other

Chief Executive Officer

18,404 0.0752%
8/2/21 Other

Chief Technology Officer

869 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
+1.69%-6.25%-60.13%-68.42% 29.82M
+1.23%-3.08%+53.96%+87.98% 55.27B
+5.09%+6.18%+63.69%+62.06% 54.15B
+0.72%-2.19%+4.36%+409.54% 23.11B
+0.25%+0.08%-17.39%-15.22% 23.22B
+1.03%-0.76%+40.14%-3.59% 20.33B
-0.37%+0.42%+37.47%-31.61% 17.91B
+0.87%-2.80%+37.96%+600.00% 15.76B
-2.54%-12.88%+168.62%+289.45% 15B
+1.22%+0.18%+25.14%+182.63% 13.82B
Average +0.92%-1.11%+35.38%+151.28% 23.86B
Weighted average by Cap. +1.56%+1.19%+46.47%+138.37%

Financials

2024 2025
Net sales 510K 448K 416K 383K 718K 49.21M 731K 4.96M 1.94M 24.03M 1.91M 1.87M 83.49M -
Net income -4.9M -4.31M -4M -3.68M -6.9M -473M -7.04M -47.75M -18.65M -231M -18.4M -18.01M -803M -7.91M -6.95M -6.46M -5.94M -11.14M -764M -11.35M -77.02M -30.08M -373M -29.68M -29.05M -1.3B
Net Debt 2.88M 2.53M 2.35M 2.16M 4.06M 278M 4.14M 28.07M 10.96M 136M 10.82M 10.59M 472M 2.73M 2.4M 2.23M 2.05M 3.84M 263M 3.91M 26.56M 10.37M 129M 10.24M 10.02M 447M
Logo ABVC BioPharma, Inc.
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.
Employees
18
Date Price Change Volume
26-07-23 US$1.200 +1.69% 69,718
26-07-22 US$1.180 -4.07% 63,641
26-07-21 US$1.230 +2.50% 41,871
26-07-20 US$1.200 -4.00% 99,622
26-07-17 US$1.250 +3.31% 88,897
  1. Stock Market
  2. Stocks
  3. ABVC Stock